Shionogi & Co., Ltd. (OTCMKTS:SGIOF – Get Free Report) is anticipated to post its results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.2771 per share and revenue of $1.12 billion for the quarter.
Shionogi & Co., Ltd. Stock Performance
SGIOF opened at $18.00 on Tuesday. The company’s 50 day moving average is $17.81 and its 200-day moving average is $19.00. Shionogi & Co., Ltd. has a 1-year low of $15.21 and a 1-year high of $26.00.
About Shionogi & Co., Ltd.
Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a focus on addressing infectious diseases and other significant unmet medical needs.
Its portfolio and development programs have included treatments for infectious diseases, central nervous system conditions, pain and other therapeutic areas. Shionogi is known for products such as Xofluza (baloxavir marboxil), an influenza treatment, and Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat bacterial infections.
Further Reading
- Five stocks we like better than Shionogi & Co., Ltd.
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Shionogi & Co. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.
